$OSMT News
Last published 4y ago
- 4y agoOSMTRVLPOsmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol "RVLP," Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceGlobeNewswire-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million -- -- Full national launch into medical a
- 4y agoOSMTRVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022GlobeNewswire-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper -- Bridgewater, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Osm
- 4y agoOSMTOsmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022GlobeNewswireBRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Op
- 4y agoALLKOPKOSMTSAN+1Thinking about buying stock in Allakos, 22nd Century Group, Osmotica Pharmaceuticals, Banco Santander SA, or Opko Health?PR NewswireNEW YORK, Dec. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALLK, XXII, OSMT, SAN, and OPK. To
- 4y agoOSMTOsmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect ConferenceGlobeNewswireBRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Op
- 4y agoOSMTOsmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business UpdateGlobeNewswireThird quarter Upneeq® product sales of $2.2 million, representing 47% growth over second quarter sales Expansion of Upneeq launch continues with introduction of Direct Dispense program in eyecare and formation of Aesthetics business unit Sale of l
- 4y agoOSMTOsmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021GlobeNewswireBRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Op
- 5y agoOSMTOsmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021GlobeNewswireBRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced that the Company will release its 2021 third quarter financial results on
- 5y agoOSMTOsmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public OfferingGlobeNewswireBRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced underwritten
- 5y agoBBIBTBTCEIOSMT+1Thinking about buying stock in Camber Energy, Bit Digital, Brickell Biotech, Osmotica Pharmaceuticals, or SmileDirectClub?PR NewswireNEW YORK, Oct. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEI, BTBT, BBI, OSMT, and SDC. To s
- 5y agoOSMTOsmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 MillionGlobeNewswireBRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced that it has entered into a note purchase agreement for up to $100 million
- 5y agoOSMTOsmotica Pharmaceuticals Announces Pricing of $35 Million Underwritten Public OfferingGlobeNewswireBRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 1
- 5y agoOSMTOsmotica Pharmaceuticals plc Announces Proposed Underwritten Public OfferingGlobeNewswireBRIDGEWATER, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its ordinary sha
- 5y agoOSMTOsmotica Pharmaceuticals plc to Present at Cantor Virtual Global Healthcare Conference 2021GlobeNewswireBRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief O
- 5y agoOSMTOsmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireBRIDGEWATER, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James "JD" S
- 5y agoOSMTOsmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLCGlobeNewswire-- Divestiture advances Company's transformation and emphasis on eye care and ocular aesthetics -- -- Proceeds of the sale will be used to retire a substantial portion of outstanding debt -- BRIDGEWATER, N.J., Aug. 30, 2021 (GLOBE NEWSWIRE) -
- 5y agoOSMTOsmotica Pharmaceuticals plc Reports Second Quarter 2021 Results and Provides Business UpdateGlobeNewswireSale of legacy business to Alora Pharmaceuticals, LLC expected to close in third quarter 2021 Second quarter 2021 total Upneeq revenue of $11.5 million including a $10.0 million milestone payment from Santen Pharmaceutical Co., Ltd Upneeq prescript
- 5y agoOSMTOsmotica Pharmaceuticals plc to Present at H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021GlobeNewswireBRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James "JD" Sc
- 5y agoOSMTOsmotica Pharmaceuticals plc to Provide Second Quarter 2021 Business and Financial Update on August 16, 2021GlobeNewswireBRIDGEWATER, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 second quarter financial
- 5y agoOSMTOsmotica Subsidiary RVL Pharmaceuticals, Focused on Eye Care and Ocular Aesthetics, Strengthens and Expands Leadership TeamGlobeNewswireBRIDGEWATER, NJ, June 30, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced that J. Aaron Green will join the leadership team of RVL Pharmace
- 5y agoCLSDOSMTPSACSIOX+1Thinking about buying stock in Osmotica Pharmaceuticals, Property Solutions Acquisition, Sio Gene Therapies, Clearside Biomedical, or Sorrento Therapeutics?PR NewswireNEW YORK, June 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OSMT, PSAC, SIOX, CLSD, and SRNE.
- 5y agoOSMTOsmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLCGlobeNewswireOsmotica will receive a $110 million upfront cash payment, with the potential to receive up to $60 million in additional milestone paymentsAlora will acquire manufacturing operations in Marietta, Georgia in addition to legacy productsOsmotica will retain
- 5y agoOSMTOsmotica Pharmaceuticals plc Announces Result of Proposal 3 at Annual General MeetingGlobeNewswireBRIDGEWATER, N.J., June 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced results of the Company's Annual General Meeting. At the Annu
- 5y agoOSMTOsmotica Pharmaceuticals plc to Present at Jefferies Virtual Healthcare Conference 2021GlobeNewswireBRIDGEWATER, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub,
- 5y agoOSMTOsmotica Pharmaceuticals plc Reports First Quarter 2021 Results and Provides Business UpdateGlobeNewswireFirst quarter 2021 total revenue of $23.9 million RVL Pharmaceuticals' Upneeq wins 2021 MedTech Breakthrough Award; gainsrecognition as outstanding health and medical technology product Upneeq sales trend higher, exhibiting strong sequential growth
- 5y agoOSMTOsmotica Pharmaceuticals Plc to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 13, 2021 / Osmotica Pharmaceuticals Plc (NASDAQ:OSMT) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time. To listen to the event live or
- 5y agoOSMTOsmotica Pharmaceuticals plc to Present at the 2021 RBC Capital Markets Global Healthcare Virtual ConferenceGlobeNewswireBRIDGEWATER, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn
- 5y agoOSMTRVL Pharmaceuticals Upneeq® Wins 2021 MedTech Breakthrough AwardGlobeNewswireBRIDGEWATER, N.J., May 10, 2021 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica"), a fully integrated biopharmaceutical company, today announced that its Upneeq® (oxymetazoline hydr
- 5y agoOSMTOsmotica Pharmaceuticals plc to Provide First Quarter 2021 Business and Financial Update on May 13, 2021GlobeNewswireBRIDGEWATER, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 first quarter financial r
- 5y agoOSMTOsmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2020 Results and Provides Business UpdateGlobeNewswireFourth quarter and full year 2020 total revenue of $34.5 million and $177.9 million, respectively Received FDA approval and subsequently introduced Upneeq® (oxymetazoline hydrochloride ophthalmic...
- 5y agoOSMTOsmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2020 Business and Financial Update on March 30, 2021GlobeNewswireBRIDGEWATER, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that...
- 5y agoOSMTOsmotica to Present at Barclays Global Healthcare Conference 2021GlobeNewswireBRIDGEWATER, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
- 5y agoOSMTOsmotica to Present at 10th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireBRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
- 5y agoOSMTDISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013GlobeNewswireBRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Ap9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i)AMENDMENT The Form 8.1(a) dealings disclosure announcement made on January 27, 2020...
- 5y agoOSMTDISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013GlobeNewswireBRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Ap9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i) IRISH TAKEOVER PANEL ...
- 5y agoOSMTDIRECTOR DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013GlobeNewswireBRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- fAp9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i) IRISH TAKEOVER PANEL ...
- 5y agoOSMTRule 2.10 AnnouncementGlobeNewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH...
- 5y agoOSMTOsmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release TabletsGlobeNewswireBRIDGEWATER, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has...
- 5y agoOSMTOsmotica Pharmaceuticals plc Announces Agreement to Settle Patent Litigation with AdamasGlobeNewswireAdamas to acquire global rights to OSMOLEX ER® for $7.5 million Company to focus on maximizing commercial opportunity for Upneeq™ BRIDGEWATER, N.J., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica...
- 5y agoOSMTRVL Pharmaceuticals, Inc. Strengthens Leadership Team as Commercial Launch of Upneeq® ExpandsGlobeNewswireBRIDGEWATER, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”), announced the addition of Dr. Raymond...
- 6y agoOSMTOsmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual London Healthcare ConferenceGlobeNewswireBRIDGEWATER, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
- 6y agoOSMTOsmotica Pharmaceuticals plc Reports Third Quarter 2020 Results and Provides Business UpdatesGlobeNewswireThird quarter 2020 total revenue of $57.2 million Received U.S Food and Drug Administration (“FDA”) approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for acquired...
- 6y agoOSMTOsmotica Pharmaceuticals plc to Provide Third Quarter 2020 Business and Financial Update on November 10, 2020GlobeNewswireBRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the...
- 6y agoOSMTJAMA Ophthalmology Publishes Pooled Analysis of Data from two Phase 3 Clinical Trials of Upneeq™ (oxymetazoline hydrochloride, 0.1% solution) for Acquired PtosisGlobeNewswire-- Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acquired...
- 6y agoOSMTOsmotica to Present at 2020 Wells Fargo Virtual Healthcare ConferenceGlobeNewswireBRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
- 6y agoOSMTOsmotica Pharmaceuticals plc Reports Second Quarter 2020 Results and Provides Business UpdatesGlobeNewswireSecond quarter 2020 total revenue of $37.5 million Received U.S Food and Drug Administration (“FDA”) approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for acquired...
- 6y agoOSMTOsmotica Pharmaceuticals plc to Provide Second Quarter 2020 Business and Financial Update and Presentation on Upneeq™ on August 11, 2020GlobeNewswireBRIDGEWATER, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the...
- 6y agoOSMTSanten and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201, a First-in-Class Treatment for Acquired BlepharoptosisGlobeNewswireOSAKA, Japan and BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd (hereinafter, Santen) and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc...
- 6y agoOSMTOsmotica Pharmaceutical US LLC Announces FDA User Fee Goal Date of December 29, 2020 for Arbaclofen Extended Release TabletsGlobeNewswireBRIDGEWATER, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) through its subsidiary Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a fully...
- 6y agoBYNDSTNGCRWDBSX+2Cramer's lightning round: I like Beyond MeatCNBC"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.